List of Excipients in Branded Drug ALENDRONATE

« Back to Dashboard

Generic Drugs Containing ALENDRONATE

Company	Ingredient	NDC	Excipient
Marlex Pharmaceuticals Inc	alendronate sodium	10135-696	CELLULOSE, MICROCRYSTALLINE
Marlex Pharmaceuticals Inc	alendronate sodium	10135-696	CROSCARMELLOSE SODIUM
Marlex Pharmaceuticals Inc	alendronate sodium	10135-696	MAGNESIUM STEARATE
Marlex Pharmaceuticals Inc	alendronate sodium tablet	10135-718	CELLULOSE, MICROCRYSTALLINE
Marlex Pharmaceuticals Inc	alendronate sodium tablet	10135-718	CROSCARMELLOSE SODIUM
Marlex Pharmaceuticals Inc	alendronate sodium tablet	10135-718	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ALENDRONATE?

# Of NDCs	Excipient
9	CELLULOSE, MICROCRYSTALLINE
9	CROSCARMELLOSE SODIUM
9	MAGNESIUM STEARATE

Alendronate Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Alendronate is a mature bisphosphonate with limited compound-patent protection and intense generic competition. The commercial opportunity is therefore concentrated in formulation performance, adherence, tolerability, combination products, and regional delivery formats rather than in conventional immediate-release tablets. Excipient selection must address three constraints: very low oral bioavailability, clinically important food and mineral interactions, and upper-gastrointestinal administration risks.[1]

What is the current regulatory and commercial status of alendronate?

Alendronate sodium is an FDA-approved oral bisphosphonate used primarily for osteoporosis treatment and prevention, including postmenopausal osteoporosis and glucocorticoid-induced osteoporosis. Merck introduced Fosamax, the reference product, in 1995. Generic alendronate sodium tablets are widely approved in 5 mg, 10 mg, 35 mg, and 70 mg strengths.[1,2]

The principal commercial products are:

Product type	Typical strength	Administration	Commercial position
Alendronate sodium tablet	5, 10, 35, or 70 mg	Once daily or once weekly, with plain water	Commodity generic market
Alendronate plus vitamin D3 tablet	70 mg alendronate plus vitamin D3	Once weekly	Combination-product opportunity
Effervescent alendronate tablet	70 mg	Dissolved in water before administration	Differentiated adherence and tolerability format
Oral solution or suspension	Product-dependent	Measured liquid dose	Niche opportunity, higher formulation complexity

Fosamax and Fosamax Plus D no longer have the commercial leverage associated with market exclusivity. The core compound and key historical product patents have expired, and generic manufacturers supply the market through the abbreviated new drug application pathway.[2,3]

Alendronate has no biosimilar exposure because it is a chemically synthesized small molecule rather than a biologic. Competitive risk comes from generic tablets, combination products, alternative bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab, and oral osteoporosis therapies.

What excipients are used in alendronate tablets?

Conventional alendronate tablets generally use standard direct-compression or wet-granulation excipients. The formulation objective is not to increase systemic exposure aggressively. It is to provide dose uniformity, mechanical strength, rapid dispersion, chemical stability, and acceptable swallowing characteristics without increasing mineral binding or gastrointestinal irritation.

Typical excipient classes include:

Excipient class	Representative materials	Primary function	Key alendronate consideration
Diluent	Microcrystalline cellulose, lactose, mannitol	Tablet mass and compressibility	Lactose may create suitability issues for some patients; mannitol can improve mouthfeel
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Tablet breakup	Fast disintegration supports consistent release
Binder	Povidone, copovidone, pregelatinized starch	Granule and tablet strength	Excess binder can delay disintegration
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and manufacturing control	Over-lubrication can reduce wetting and dissolution
Glidant	Colloidal silicon dioxide	Powder flow	Useful for low-dose uniformity and high-speed compression
Sweetener or flavor	Sucralose, saccharin, flavors	Palatability in dissolved or chewable formats	Important for effervescent and liquid products
Buffer system	Citric acid, sodium bicarbonate, sodium carbonate	pH control and effervescence	Can improve administration but increases sodium and packaging requirements
Film coating	Hypromellose, titanium dioxide, polyethylene glycol	Identification, protection, swallowability	Coating must not materially delay dispersion

The active ingredient is usually supplied as alendronate sodium trihydrate or an equivalent alendronate sodium form. The final product must be labeled in terms of alendronic acid equivalent where applicable.[1]

The most important excipient exclusion is calcium or other polyvalent mineral material in the immediate-release dosage form. Calcium, magnesium, iron, and aluminum can form poorly absorbed complexes with alendronate. The FDA label instructs patients to take alendronate with plain water and to delay food, beverages, calcium supplements, antacids, and other oral medicines.[1]

How does alendronate absorption affect excipient strategy?

Alendronate has extremely low and variable oral bioavailability. Under fasting conditions, only a small fraction of the dose reaches systemic circulation. Administration with coffee, juice, food, or mineral-containing water materially reduces absorption.[1]

Excipient strategy must therefore preserve the fasting administration requirement rather than attempt to compensate through conventional solubilization. A formulation that increases dissolution but also promotes interaction with calcium or other cations may reduce clinical performance.

The main formulation design principles are:

1. Avoid mineral-containing excipients. Calcium carbonate, calcium phosphate, magnesium salts, iron salts, and aluminum-containing materials are unsuitable for the alendronate-containing portion of a dosage form unless physical separation and administration instructions are tightly controlled.

2. Control microenvironmental pH. Alendronate is highly polar and ionized. Buffer selection can affect chemical stability, dissolution, taste, and gastrointestinal tolerability.

3. Promote rapid disintegration. A rapidly dispersing tablet can reduce the residence time of concentrated drug in the esophagus and stomach, although it does not remove the need for upright posture and adequate water intake.

4. Manage sodium load. Alendronate sodium products already contain a sodium counterion. Effervescent systems add sodium bicarbonate or sodium carbonate, creating a potential labeling and patient-selection issue.

5. Avoid excipient interactions that mimic food effects. Hydrophobic lubricants, poorly wetting coatings, and high-viscosity polymers may delay drug dispersion and create variability in the fasting state.

What formulations are protected by alendronate patents?

The original alendronate compound and core Fosamax product protection are no longer meaningful barriers to generic immediate-release tablets in the United States. Historical protection included the alendronate compound patent, commonly identified as U.S. Patent No. 4,621,077, together with later patents covering dosing regimens and product combinations.[3,4]

The main patent categories were:

Patent category	Historical subject matter	Current commercial significance
Compound patents	Alendronate and related aminobisphosphonates	Expired
Daily and weekly dosing	Reduced-frequency administration and osteoporosis treatment	Historical; generally expired
Combination products	Alendronate with vitamin D3	Expired or no longer a major barrier
Solid dosage forms	Tablets and manufacturing processes	Most relevant protection has expired
Effervescent or buffered products	Dissolved administration, taste, and pH control	Product-specific patents may have existed, but ordinary generic tablet entry is not blocked
Manufacturing processes	Granulation, compression, and stability	Possible process freedom-to-operate issues remain jurisdiction-specific

An applicant pursuing a new alendronate product should focus its freedom-to-operate review on active formulation, process, packaging, and method-of-use claims in each target jurisdiction. The absence of a core composition patent does not eliminate risk from later patents on a specific effervescent system, taste-masking approach, fixed-dose combination, or administration method.

When does alendronate lose exclusivity?

Alendronate lost effective U.S. market exclusivity years ago. Generic entry began after expiration of the principal Fosamax protections, with multiple manufacturers subsequently receiving FDA approvals for alendronate sodium tablets.[2,3]

Milestone	Approximate timing	Implication
Fosamax FDA approval	1995	Originator launch
Core patent and regulatory protection period	Early to late 2000s	Historical barrier to generic entry
Initial generic tablet approvals	2008 onward	Rapid price competition
Current status	Mature generic market	Low barrier for conventional tablets; higher barrier for differentiated products

The exact enforceability of any historical patent depends on the jurisdiction, claim scope, terminal disclaimers, patent-term adjustments, and litigation history. For current U.S. commercial planning, the principal issue is not compound exclusivity. It is whether a proposed product has differentiated clinical or usability value sufficient to support a premium.

What is the Orange Book status of alendronate?

The FDA Orange Book is the primary source for listed patents, exclusivity, therapeutic-equivalence evaluations, and reference-listed-drug status.[2]

Conventional alendronate sodium tablets are generally evaluated against the applicable reference products and may receive therapeutic-equivalence ratings when they meet FDA requirements. A generic applicant must still address:

• bioequivalence;
• assay and content uniformity;
• dissolution;
• impurity and degradation profiles;
• labeling conformity;
• stability;
• tablet robustness;
• container-closure performance; and
• any listed patent certifications.

For an ordinary alendronate tablet, the regulatory pathway is relatively predictable. A new effervescent tablet, oral solution, orally disintegrating tablet, or fixed-dose combination may require a different regulatory strategy, particularly if it changes administration, labeling, dosage form, or clinical instructions.

What Paragraph IV challenges and litigation affect alendronate?

The major Paragraph IV activity surrounding alendronate occurred during the original generic-entry period. Generic manufacturers challenged or designed around historical Fosamax patents, and the market subsequently moved to broad generic supply.[3,5]

Current litigation risk is more likely to arise from:

• formulation patents on effervescent or buffered dosage forms;
• patents covering taste masking or palatability systems;
• combination products containing vitamin D3 or calcium;
• manufacturing-process patents;
• method-of-use claims involving dosing frequency or patient subgroups; and
• trademark, labeling, and product-design disputes.

A Paragraph IV strategy for a conventional 70 mg alendronate tablet has limited commercial differentiation because many approved competitors already exist. A Paragraph IV challenge against a branded effervescent or specialty product may have greater value if the product commands a premium and has limited substitutable competition.

Settlement agreements from the historical generic-entry period should be reviewed for launch dates, authorized-generic provisions, covenants not to sue, and restrictions on specific dosage forms. They are unlikely to create a broad current barrier to standard generic tablets, but product-specific provisions can affect a targeted launch.

What commercial opportunities exist for alendronate excipients?

The strongest opportunity is a differentiated product that improves use without claiming a major increase in bioavailability.

Effervescent and buffered tablets

An effervescent product converts a tablet into a measured aqueous dose. This approach can improve swallowing for patients who have difficulty taking conventional tablets and can support a more acceptable administration experience. Binosto is the best-known example of this product concept in the U.S. market.[6]

The excipient platform generally requires:

• an acid-base effervescent pair;
• controlled dissolution and carbon dioxide release;
• pH buffering;
• moisture-protective packaging;
• flavor and sweetener systems;
• low-hygroscopicity processing; and
• clear instructions for complete dissolution before administration.

Commercial limitations include higher packaging costs, sensitivity to humidity, sodium exposure, larger patient instructions, and the need to demonstrate that the new format does not introduce clinically meaningful changes in exposure or tolerability.

Low-swallowing-burden tablets

Smaller, thinner, film-coated, or rapidly dispersing tablets could address swallowing concerns. Mannitol-based fillers, optimized disintegrants, and low-friction coatings can support this design. The product must remain robust during transport and must not fragment prematurely.

Alendronate plus vitamin D3

Combination products reduce pill burden and align with osteoporosis treatment routines. The key technical issue is excipient and active compatibility. Vitamin D3 is lipophilic, while alendronate is highly polar and mineral-sensitive. A formulation may require separate granules, protective coating, or controlled distribution of the two actives.

The combination has clear commercial logic, but competition includes generic alendronate and inexpensive over-the-counter vitamin D products. The premium must come from convenience, adherence, or prescribing-channel access.

Oral liquid and unit-dose formats

A liquid could address patients unable to swallow tablets, but alendronate's potency, taste, chemical behavior, and mineral-binding profile complicate development. The formulation must control sedimentation, dose uniformity, container adsorption, microbial quality, and administration accuracy.

Unit-dose sachets or premeasured cups may provide a more defensible commercial format than a multidose bottle. Packaging must prevent contact with calcium-containing materials and maintain stability across temperature and humidity conditions.

Pediatric and special-population products

Pediatric osteoporosis applications are limited and specialist-driven. A liquid or dispersible format could have value in selected populations, but the market is substantially smaller than postmenopausal osteoporosis. Regulatory and clinical development costs would require a clear orphan, hospital, or specialty-pharmacy strategy.

How strong is the alendronate patent estate?

The patent estate is weak for standard oral tablets and stronger only where the product incorporates new technical elements.

Product concept	Patent strength	Main defensive assets
Standard 70 mg tablet	Low	Manufacturing efficiency, supply reliability, regulatory approvals
Alendronate plus vitamin D3	Low to moderate	Specific composition, process, packaging, or method claims
Effervescent tablet	Moderate	Buffer system, taste, dissolution, moisture protection, administration method
Oral solution	Moderate	Stability, container interaction, dosing system, formulation composition
Orally disintegrating tablet	Low to moderate	Taste masking, mechanical properties, rapid dispersion
Novel delivery system	Moderate to high if clinically differentiated	Formulation, device, pharmacokinetic, and method-of-use claims

Patent value will depend on claim breadth and proof of clinical or commercial differentiation. A narrow patent covering a particular buffer ratio may provide limited protection if competitors can use a different acid-base system. A broader platform claim covering a stable, palatable, rapidly dissolving alendronate dosage form would have greater strategic value but would face higher validity and enablement risk.

How does alendronate compare with competing osteoporosis drugs?

Alendronate remains attractive because of low cost, long clinical experience, weekly dosing, and generic availability. Its main disadvantages are administration restrictions, gastrointestinal warnings, and poor adherence to the required fasting and upright-posture instructions.[1]

Therapy	Administration	Generic pressure	Excipient opportunity
Alendronate	Weekly oral tablet or specialty format	Very high	Adherence, swallowing, taste, combination products
Risedronate	Oral or monthly options	High	Modified-release and dosing convenience
Ibandronate	Monthly oral or injectable	Moderate to high	Frequency and tolerability
Zoledronic acid	Intravenous infusion	Lower at product level	Infusion logistics, not oral excipients
Denosumab	Subcutaneous injection	Biosimilar and follow-on risk	Device and injection experience
Teriparatide and abaloparatide	Injectable	Follow-on competition	Device, stability, and administration
Romosozumab	Monthly injection	Limited direct generic competition	Device and biologic manufacturing

Alendronate's low acquisition cost makes it difficult for excipient innovation alone to support a large premium. A successful product must reduce a recognized barrier, such as swallowing difficulty, dosing errors, or treatment discontinuation.

What generic entry risks exist for alendronate?

Generic entry risk is effectively established for standard tablets. The relevant commercial risks are:

• price erosion from additional suppliers;
• pharmacy substitution;
• procurement concentration;
• shortages caused by low-margin manufacturing;
• private-label competition;
• substitution with other generic bisphosphonates;
• reduced prescriber attention; and
• reimbursement limits on premium formulations.

A branded differentiated product may retain pricing power if it has a distinct National Drug Code, separate prescribing instructions, superior adherence data, or a reimbursement pathway that recognizes the clinical value of the formulation.

What manufacturing and IP barriers affect alendronate?

Manufacturing is technically manageable but requires disciplined control of powder handling, low-dose uniformity, moisture, and cross-contamination. Effervescent products present the highest manufacturing burden because acid-base systems are moisture-sensitive and can lose performance during storage.

Key manufacturing and intellectual-property barriers include:

• validated control of alendronate assay and impurities;
• segregation or containment during production;
• excipient compatibility under accelerated stability conditions;
• moisture-resistant blister or tube packaging;
• complete dissolution validation for effervescent products;
• scale-up of taste-masking systems;
• control of vitamin D3 distribution in combination tablets;
• dissolution-method reproducibility; and
• process patents covering granulation or compression parameters.

Geographic coverage must be reviewed separately. U.S. patent expiry does not establish freedom to operate in Europe, Japan, China, Canada, or emerging markets. Regulatory requirements, reference products, patent-term rules, and generic substitution practices differ by country.

What licensing deals could create value?

The most attractive licensing targets are not rights to generic alendronate API. They are formulation platforms with one or more of the following characteristics:

• a protected effervescent or buffered dosage form;
• adherence or persistence data;
• a ready-to-file abbreviated or hybrid regulatory package;
• established manufacturing capacity;
• proprietary moisture-barrier packaging;
• a vitamin D3 combination with demonstrated stability;
• pediatric or dysphagia-use data; or
• distribution rights in markets where generic penetration is incomplete.

A license should be valued against expected premium duration, development cost, patent term, regulatory pathway, reimbursement position, and the number of likely design-around formulations. For standard tablets, a supply or contract-manufacturing agreement is usually more rational than a royalty-bearing license.

Key Takeaways

• Alendronate's core U.S. exclusivity has expired, and standard tablets are a mature generic market.
• Excipient innovation should target administration, adherence, swallowing, taste, and combination convenience.
• Calcium, magnesium, iron, aluminum, and other mineral-containing excipients require strict control because they can reduce alendronate absorption.
• Effervescent and buffered formulations offer the clearest differentiated-product opportunity but require moisture-resistant packaging and higher manufacturing controls.
• Alendronate plus vitamin D3 can reduce pill burden, although low-cost generic vitamin D limits premium potential.
• A standard tablet has weak patent defensibility. Effervescent, liquid, taste-masked, and specialty formats can support stronger formulation and process claims.
• Biosimilar risk does not apply. Generic and therapeutic substitution remain the primary competitive threats.
• Commercial success depends on measurable adherence or tolerability advantages, not simply a new excipient blend.

FAQs

Can calcium carbonate be used in an alendronate formulation?

Calcium carbonate should not be incorporated into the immediate-release alendronate-containing portion because calcium can bind alendronate and reduce absorption. A separate, clearly controlled combination product requires specific formulation, labeling, and clinical evaluation.

Which excipient is best for an alendronate orally disintegrating tablet?

Mannitol is a common starting point for mouthfeel and compactability, combined with a fast disintegrant and a validated taste-masking system. The final choice depends on dissolution, palatability, tablet strength, moisture sensitivity, and bioequivalence performance.

Does an effervescent alendronate product improve bioavailability?

The primary value is administration and adherence, not necessarily higher bioavailability. The product must still be taken according to fasting instructions and must demonstrate acceptable exposure relative to the relevant reference product.

Can alendronate be developed as an over-the-counter product?

An OTC switch would require FDA evaluation of self-selection, labeling comprehension, safe use, and the risks associated with esophageal injury, hypocalcemia, renal impairment, and administration errors. The current prescription-use framework remains the established U.S. model.

What is the best commercial niche for a new alendronate product?

The strongest niche is a stable, palatable, easy-to-administer weekly product for patients who struggle with conventional tablets. A combination with vitamin D3 is commercially viable but faces stronger generic price competition.

References

1. U.S. Food and Drug Administration. (2023). Fosamax (alendronate sodium) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2008). FDA approves first generic versions of Fosamax tablets. FDA.

4. U.S. Patent and Trademark Office. (1980). U.S. Patent No. 4,621,077: 1-Hydroxyethane-1,1-diphosphonic acid derivatives. USPTO.

5. Federal Trade Commission. (2002). Generic drug entry and patent litigation materials relating to alendronate. FTC.

6. U.S. Food and Drug Administration. (2024). Binosto (alendronate sodium) effervescent tablets prescribing information. FDA.